Related Experiment Videos
[Levodopa in hemifacial spasm. A therapeutic alternative]
R O Millán-Guerrero1, E Tene-Pérez, B Trujillo-Hernández
1Servicio de Neurología, Hospital General de Zona UMF 1 IMSS, Colima, Col.
Gaceta Medica De Mexico
|December 29, 2000
Summary
Levodopa/carbidopa effectively treats hemifacial spasm, reducing symptoms by 75% in a 4-year study. This treatment offers a cost-effective alternative, enabling patients to lead normal lives.
Area of Science:
- Neurology
- Pharmacology
Background:
- Hemifacial spasm (HFS) is a neurological disorder characterized by involuntary contractions of facial muscles.
- Current treatments for HFS have limitations, necessitating exploration of alternative therapeutic options.
Observation:
- A study investigated Levodopa/carbidopa as a potential treatment for hemifacial spasm.
- Three patients with a 5-year history of HFS participated in a cross-over study, acting as their own controls.
Findings:
- Levodopa/carbidopa administration resulted in the disappearance of hemifacial spasm symptoms within two weeks.
- Symptom recurrence was observed upon placebo administration, with symptom reduction returning upon reintroduction of Levodopa.
- Sustained treatment over four years demonstrated an average reduction of 75% in hemifacial spasm severity.
Implications:
- Levodopa/carbidopa presents a viable and effective therapeutic alternative for managing hemifacial spasm.
- This treatment option is economically accessible and significantly improves patients' quality of life, allowing them to resume normal daily activities.